more than 90% effective, as Pfizer’s seems to be, governments will be able to persuade
most people to turn up for a jab.
All this amounts to a daunting agenda for governments. They must communicate clearly
about the scientific rationale for approvals and the criteria for distribution. They must
invest in supply chains and training, knowing that some spending will be wasted. And
they will need to explain to their citizens how the whole world gains if countries work
together to distribute vaccines fairly.
Edward Carr: deputy editor, The Economist
| Section menu | Main menu |